HORMAD2 dysregulation through either SNPs [32, 33] or hypermethylation [34] is attributed to poor survival in non-small cell lung cancer (NSCLC) and thyroid carcinoma. Here, HORMAD2 is linked to non-small cell lung carcinoma.